This section offers a closer look to TransQST activities through interviews to project partners. These interviews also have the aim to provide deeper insights into the application and applicability of the project results, while introducing the members of the teams working behind the scenes.
What is IFADO’s main focus? Our passion is liver physiology, hepatotoxicity and functional imaging. How has participating in TransQST impacted your company? We had the chance to find partners with common interests and complementary technologies; this allowed us to establish exciting collaborations. What challenges has IFADO faced across the project? What are your main achievements […]Read moreMore Tag
What is UOXF´s main focus? We are the Computational Cardiovascular Science Team, based at the Department of Computer Science of the University of Oxford (UK). Our expertise is in human-based computational modelling and simulation for in silico trials and cardiovascular research, to integrate and expand the information extracted from a range of experimental and clinical […]Read moreMore Tag
What is AZ’s main focus? The academia-industry hybrid environment in TransQST enabled AZ, together with other consortium members, to develop novel mathematical and biological modelling solutions that maximize study subject’s safety during drug development. In particular, we were interested in optimizing the use of preclinical information by developing mathematical models to facilitate the transition from […]Read moreMore Tag
What is CrownBio´s main focus? Crown Biosciences Netherlands, formerly OcellO, is part of the global contract research organization (CRO) Crown Bioscience. Crown Bioscience is known for its extensive collection of PDX models that are used for in vivo testing. Since 2018 CrownBio also offers in vitro organoid services and upon acquisition of OcellO it is […]Read moreMore Tag
What is SIMCYP-Certara’s main focus? Providing in silico solutions to speed-up drug discovery and development: basically, getting safer, more effective drugs to patients faster. By ‘in silico’ we mean data handling, analysis and visualization, modelling & simulation. For example, our tools facilitate and improve decision making in drug discovery, safety and DMPK (drug metabolism and […]Read moreMore Tag